Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, et al. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol 2022;49:179-183.
PMID: 34661314